Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy - A meta-analysis of 11 randomized controlled trials involving 21,295 participants

Pharmacological Research

Volumn 72, Issue , 2013, Pages 35-44

  Barylski, Marcin ^a   Nikfar, Shekoufeh ^b,c   Mikhailidis, Dimitri P ^d   Toth, Peter P ^e   Salari, Pooneh ^f   Ray, Kausik K ^g   Pencina, Michael J ^h   Rizzo, Manfredi ^i,j   Rysz, Jacek ^a   Abdollahi, Mohammad ^k   Nicholls, Stephen J ^l   Banach, Maciej ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^e UNIVERSITY OF ILLINOIS   (United States)

^f TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^g ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^h BOSTON UNIVERSITY   (United States)

ⁱ UNIVERSITY OF PALERMO   (Italy)

^j Euro Mediterranean Institute of Science and Technology   (Italy)

^k TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^l UNIVERSITY OF ADELAIDE   (Australia)

more..

Author keywords

Cardiovascular events; Chronic kidney disease; Dialysis; Mortality; Statins; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; DRUG EFFICACY; DRUG FATALITY; FEMALE; HEART DISEASE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT DURATION;

CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; STROKE;

EID: 84876963176     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2013.03.007     Document Type: Article

References (45)

1. M. Banach, D.P. Mikhailidis, S.E. Kjeldsen, and J. Rysz Time for new indications for statins? Medical Science Monitor 15 2009 MS1 MS5
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group New England Journal of Medicine 339 1998 1349 1357
4. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
5. D. Nikolic, S. Nikfar, P. Salari, M. Rizzo, K.K. Ray, and M.J. Pencina Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials Current Medical Research and Opinion 2013 10.1185/03007995.2013.779237
6. J. Rysz, W.S. Aronow, R.S. Stolarek, S. Hannam, D.P. Mikhailidis, and M. Banach Nephroprotective and clinical potential of statins in dialyzed patients Expert Opinion on Therapeutic Targets 13 2009 541 550
7. G. O'Driscoll, D. Green, and R.R. Taylor Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month Circulation 95 1997 1126 1131
8. W.F. Keane, B.L. Kasiske, M.P. O'Donnell, and Y. Kim The role of altered lipid metabolism in the progression of renal disease: experimental evidence American Journal of Kidney Diseases 17 Suppl. 1 1991 8 42
9. J.M. Vieira, L.T. Rodrigues, E. Mantovani, H. Dellê, A.L. Mattar, and D.M. Malheiros Statin monotherapy attenuates renal injury in a salt-sensitive hypertension model of renal disease Nephron Physiology 101 2005 82 91
10. A. Yoshimura, T. Nemoto, Y. Sugenoya, K. Inui, S. Watanabe, and Y. Inoue Effect of simvastatin on proliferative nephritis and cell-cycle protein expression Kidney International. Supplement 71 1999 S84 S87
11. X.Y. Zhu, E. Daghini, A. Chade, C. Napoli, E.L. Ritman, and A. Lerman Simvastatin prevents coronary microvascular remodelling in renovascular hypertensive pigs Journal of the American Society of Nephrology 18 2007 1209 1217
12. M. Tonelli Statins for slowing kidney disease progression: an as yet unproven indication American Journal of Kidney Diseases 52 2008 391 394
13. S.L. Seliger, N.S. Weiss, D.L. Gillen, B. Kestenbaum, A. Ball, and D.J. Sherrard HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients Kidney International 61 2002 297 304
14. M. Tonelli, L. Moye, F.M. Sacks, B. Kiberd, and G. Curhan Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency Annals of Internal Medicine 138 2003 98 104
15. C. Wanner, V. Krane, W. März, M. Olschewski, J.F. Mann, and G. Ruf Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis New England Journal of Medicine 353 2005 238 248
16. B.C. Fellström, A.G. Jardine, R.E. Schmieder, H. Holdaas, K. Bannister, and J. Beutler Rosuvastatin and cardiovascular events in patients undergoing hemodialysis New England Journal of Medicine 360 2009 1395 1407
17. C. Baigent, M.J. Landray, C. Reith, J. Emberson, D.C. Wheeler, and C. Tomson The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial Lancet 377 2011 2181 2192
18. A.R. Jadad Randomised controlled trials 1998 BMJ Books London, UK
19. R.G. Fassett, I.K. Robertson, M.J. Ball, D.P. Geraghty, and J.S. Coombes Effect of atorvastatin on kidney function in chronic kidney disease: a randomized double-blind placebo-controlled trial Atherosclerosis 213 2010 218 224
20. V.G. Athyros, D.P. Mikhailidis, E.N. Liberopoulos, A.I. Kakafika, A. Karagiannis, and A.A. Papageorgiou Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome. a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study Nephrology, Dialysis, Transplantation 22 2007 118 127
21. H. Nakamura, K. Mizuno, Y. Ohashi, T. Yoshida, K. Hirao, and Y. Uchida Pravastatin and cardiovascular risk in moderate chronic kidney disease Atherosclerosis 206 2009 512 517
22. P.M. Ridker, J. MacFadyen, M. Cressman, and R.J. Glynn Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial Journal of the American College of Cardiology 55 2010 1266 1273
23. B.G. Stegmayr, M. Brännstrom, S. Bucht, V. Crougneau, E. Dimeny, and A. Ekspong Low-dose atorvastatin in severe chronic kidney disease patients: a randomized controlled endpoint study Scandinavian Journal of Urology and Nephrology 39 2005 489 497
24. D. Saltissi, C. Morgan, R.J. Rigby, and J. Westhuyzen Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis American Journal of Kidney Diseases 39 2002 283 290
25. J. Kendrick, M.G. Shilpak, G. Targher, T. Cook, J. Lindeneld, and M. Chonchol Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study Trial American Journal of Kidney Diseases 55 2010 42 49
26. P.W.B. Nanayakkara, C. van Guldener, P.M. ter Wee, P.G. Scheffer, F.J. van Ittersum, and J.W. Twisk Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function and renal function in patients with mild to moderate chronic kidney disease Archives of Internal Medicine 167 2007 1262 1270
27. Banach M, Nikfar S, Rahimi R, Bielecka-Dabrowa A, Pencina MJ, Mikhailidis DP, et al. The effects of statins on blood pressure in normotensive or hypertensive subjects - a meta-analysis of randomized controlled trials. International Journal of Cardiology, in press, http://dx.doi.org/10.1016/j. ijcard.2013.03.068.
28. B. Franczyk-Skóra, A. Gluba, M. Banach, D. Kozłowski, J. Małyszko, and J. Rysz Prevention of sudden cardiac death in patients with chronic kidney disease BMC Nephrology 13 2012 162
29. A.S. Go, G.M. Chertow, D. Fan, C.E. McCulloch, and C. Hsu Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization New England Journal of Medicine 351 2004 1296 1305
30. M. Tonelli, A. Keech, J. Shepherd, F. Sacks, A. Tonkin, and C. Packard Effect of pravastatin in people with diabetes and chronic kidney disease Journal of the American Society of Nephrology 16 2005 3748 3754
31. J. Shepherd, J.P. Kastelein, V.A. Bittner, R. Carmena, P.C. Deedwania, and A. Breazna Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease Mayo Clinic Proceedings 83 2008 870 879
32. V.G. Athyros, A.I. Hatzitolios, A. Karagiannis, C. Savopoulos, N. Katsiki, and K. Tziomalos IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis Archives of Medical Science 7 2011 984 992
33. M. Chonchol, T. Cook, J. Kjekshus, T.R. Pedersen, and J. Lindenfeld Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency American Journal of Kidney Diseases 49 2007 373 382
34. M.J. Koren, M.H. Davidson, D.J. Wilson, R.S. Fayyad, A. Zuckerman, and D.P. Reed Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD American Journal of Kidney Diseases 53 2009 741 750
35. M. Tonelli, C. Isles, G.C. Curhan, A. Tonkin, M.A. Pfeffer, and J. Shepherd Effect of pravastatin on cardiovascular events in people with chronic kidney disease Circulation 110 2004 1557 1563
36. S.D. Navaneethan, F. Pansini, V. Perkovic, C. Manno, F. Pellegrini, and D.W. Johnson HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis Cochrane Database of Systematic Reviews 2 2009 CD007784
37. G.F. Strippoli, S.D. Navaneethan, D.W. Johnson, V. Perkovic, F. Pellegrini, and A. Nicolucci Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials BMJ 22 2008 645 651
38. H.M. Colhoun, D.J. Betteridge, P.N. Durrington, G.A. Hitman, H.A. Neil, and S.J. Livingstone Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS) American Journal of Kidney Diseases 54 2009 810 819
39. F.W. Asselbergs, G.F. Diercks, H.L. Hillege, A.J. van Boven, W.M. Janssen, and A.A. Voors Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria Circulation 110 2004 2809 2816
40. M. Barylski, J. Małyszko, J. Rysz, M. Myśliwiec, and M. Banach Lipids, blood pressure, kidney - what was new in 2011? Archives of Medical Science 7 2011 1055 1066
41. M. Banach, D. Hering, K. Narkiewicz, M. Mysliwiec, J. Rysz, and J. Malyszko Lipids, blood pressure, kidney - what was new in 2012? International Journal of Pharmacology 8 2012 659 678
42. A. Gluba, J. Rysz, and M. Banach Statins in patients with chronic kidney disease: why, who and when? Expert Opinion on Pharmacotherapy 11 2010 2665 2674
43. A.F.G. Cicero, A. Reggi, A. Parini, and C. Borghi Application of polyunsaturated fatty acids in internal medicine: beyond the established cardiovascular effects Archives of Medical Science 8 2012 784 793
44. A. Poli, M. Casula, E. Tragni, O. Brignoli, A. Filippi, and C. Cricelli Reaching LDL-c targets in high-risk patients requires high-efficacy cholesterol-lowering drugs in more than 50% of cases. The results of the CHECK study Pharmacological Research 64 2011 393 396
45. C. Wanner, and V. Krane Uremia-specific alterations in lipid metabolism Blood Purification 20 2002 451 453